Its original target was the chimeric protein, BCR-ABL, formed as a result of the molecular juxtaposition of two genes, BCR and ABL, on a newly created Philadelphia chromosome in chronic myelogenous leukaemia (CML) patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.